APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza NA Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Influenza NA Inhibitor Market Outlook and Growth Opportunities 2026

2 January 2026191 pages

Choose your research edition.

Industry ResearchInfluenza NA Inhibitor Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza NA Inhibitor Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Influenza NA Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza NA Inhibitor Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza NA Inhibitor Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Influenza NA Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Influenza NA Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Influenza NA Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenza NA Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Influenza NA Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Influenza NA Inhibitor market include ATK Chemical, Chemwill Asia Co.,Ltd., Green Cross, Moksha8 Pharma, NeoPharm, Shionogi Co., GlaxoSmithKline, Henan DaKen Chemical and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Influenza NA Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Influenza NA Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Influenza NA Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Influenza NA Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Influenza NA Inhibitor Segment by Company

ATK Chemical

Chemwill Asia Co.,Ltd.

Green Cross

Moksha8 Pharma

NeoPharm

Shionogi Co.

GlaxoSmithKline

Henan DaKen Chemical

Roche

Influenza NA Inhibitor Segment by Type

Zanamivir

Peramivir

Oseltamivir

Influenza NA Inhibitor Segment by Application

Influenza A Treatment

Influenza B Treatment

Influenza NA Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Influenza NA Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Influenza NA Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Influenza NA Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze Influenza NA Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza NA Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza NA Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza NA Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Influenza NA Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Influenza NA Inhibitor industry.

Chapter 3: Detailed analysis of Influenza NA Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Influenza NA Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Influenza NA Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Influenza NA Inhibitor Industry Trends Table 2. Influenza NA Inhibitor Industry Drivers Table 3. Influenza NA Inhibitor Industry Opportunities and Challenges Table 4. Influenza NA Inhibitor Industry Restraints Table 5. Global Influenza NA Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Influenza NA Inhibitor Revenue Share by Company (2021-2026) Table 7. Global Influenza NA Inhibitor Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Influenza NA Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global Influenza NA Inhibitor Average Price (US$/Kg) of Company (2021-2026) Table 10. Global Influenza NA Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global Influenza NA Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global Influenza NA Inhibitor Company, Product Type & Application Table 13. Global Influenza NA Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Influenza NA Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Zanamivir Table 18. Significant Companies of Peramivir Table 19. Significant Companies of Oseltamivir Table 20. Global Influenza NA Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 21. Global Influenza NA Inhibitor Sales Volume by Type (2021-2026) & (Tons) Table 22. Global Influenza NA Inhibitor Sales Volume by Type (2027-2032) & (Tons) Table 23. Global Influenza NA Inhibitor Sales Volume Share by Type (2021-2026) Table 24. Global Influenza NA Inhibitor Sales Volume Share by Type (2027-2032) Table 25. Global Influenza NA Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Influenza NA Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Influenza NA Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Influenza NA Inhibitor Sales Value Share by Type (2021-2026) Table 29. Global Influenza NA Inhibitor Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Influenza A Treatment Table 31. Significant Companies of Influenza B Treatment Table 32. Global Influenza NA Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 33. Global Influenza NA Inhibitor Sales Volume by Application (2021-2026) & (Tons) Table 34. Global Influenza NA Inhibitor Sales Volume by Application (2027-2032) & (Tons) Table 35. Global Influenza NA Inhibitor Sales Volume Share by Application (2021-2026) Table 36. Global Influenza NA Inhibitor Sales Volume Share by Application (2027-2032) Table 37. Global Influenza NA Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Influenza NA Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Influenza NA Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Influenza NA Inhibitor Sales Value Share by Application (2021-2026) Table 41. Global Influenza NA Inhibitor Sales Value Share by Application (2027-2032) Table 42. Global Influenza NA Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 43. Global Influenza NA Inhibitor Sales by Region (2021-2026) & (Tons) Table 44. Global Influenza NA Inhibitor Sales Market Share by Region (2021-2026) Table 45. Global Influenza NA Inhibitor Sales by Region (2027-2032) & (Tons) Table 46. Global Influenza NA Inhibitor Sales Market Share by Region (2027-2032) Table 47. Global Influenza NA Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Influenza NA Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Influenza NA Inhibitor Sales Value Share by Region (2021-2026) Table 50. Global Influenza NA Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Influenza NA Inhibitor Sales Value Share by Region (2027-2032) Table 52. Global Influenza NA Inhibitor Market Average Price (US$/Kg) by Region (2021-2026) Table 53. Global Influenza NA Inhibitor Market Average Price (US$/Kg) by Region (2027-2032) Table 54. Global Influenza NA Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 55. Global Influenza NA Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Influenza NA Inhibitor Sales by Country (2021-2026) & (Tons) Table 57. Global Influenza NA Inhibitor Sales Market Share by Country (2021-2026) Table 58. Global Influenza NA Inhibitor Sales by Country (2027-2032) & (Tons) Table 59. Global Influenza NA Inhibitor Sales Market Share by Country (2027-2032) Table 60. Global Influenza NA Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Influenza NA Inhibitor Sales Value Market Share by Country (2021-2026) Table 62. Global Influenza NA Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Influenza NA Inhibitor Sales Value Market Share by Country (2027-2032) Table 64. ATK Chemical Company Information Table 65. ATK Chemical Business Overview Table 66. ATK Chemical Influenza NA Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 67. ATK Chemical Influenza NA Inhibitor Product Portfolio Table 68. ATK Chemical Recent Development Table 69. Chemwill Asia Co.,Ltd. Company Information Table 70. Chemwill Asia Co.,Ltd. Business Overview Table 71. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 72. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product Portfolio Table 73. Chemwill Asia Co.,Ltd. Recent Development Table 74. Green Cross Company Information Table 75. Green Cross Business Overview Table 76. Green Cross Influenza NA Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 77. Green Cross Influenza NA Inhibitor Product Portfolio Table 78. Green Cross Recent Development Table 79. Moksha8 Pharma Company Information Table 80. Moksha8 Pharma Business Overview Table 81. Moksha8 Pharma Influenza NA Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 82. Moksha8 Pharma Influenza NA Inhibitor Product Portfolio Table 83. Moksha8 Pharma Recent Development Table 84. NeoPharm Company Information Table 85. NeoPharm Business Overview Table 86. NeoPharm Influenza NA Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 87. NeoPharm Influenza NA Inhibitor Product Portfolio Table 88. NeoPharm Recent Development Table 89. Shionogi Co. Company Information Table 90. Shionogi Co. Business Overview Table 91. Shionogi Co. Influenza NA Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 92. Shionogi Co. Influenza NA Inhibitor Product Portfolio Table 93. Shionogi Co. Recent Development Table 94. GlaxoSmithKline Company Information Table 95. GlaxoSmithKline Business Overview Table 96. GlaxoSmithKline Influenza NA Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 97. GlaxoSmithKline Influenza NA Inhibitor Product Portfolio Table 98. GlaxoSmithKline Recent Development Table 99. Henan DaKen Chemical Company Information Table 100. Henan DaKen Chemical Business Overview Table 101. Henan DaKen Chemical Influenza NA Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 102. Henan DaKen Chemical Influenza NA Inhibitor Product Portfolio Table 103. Henan DaKen Chemical Recent Development Table 104. Roche Company Information Table 105. Roche Business Overview Table 106. Roche Influenza NA Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 107. Roche Influenza NA Inhibitor Product Portfolio Table 108. Roche Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Influenza NA Inhibitor Distributors List Table 112. Influenza NA Inhibitor Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Influenza NA Inhibitor Product Image Figure 2. Global Influenza NA Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza NA Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global Influenza NA Inhibitor Sales (2021-2032) & (Tons) Figure 5. Global Influenza NA Inhibitor Sales Average Price (US$/Kg) & (2021-2032) Figure 6. Global Influenza NA Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Zanamivir Image Figure 10. Peramivir Image Figure 11. Oseltamivir Image Figure 12. Global Influenza NA Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 13. Global Influenza NA Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Influenza NA Inhibitor Sales Volume Share by Type (2021-2032) Figure 15. Global Influenza NA Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Influenza NA Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Influenza NA Inhibitor Sales Value Share by Type (2021-2032) Figure 18. Influenza A Treatment Image Figure 19. Influenza B Treatment Image Figure 20. Global Influenza NA Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 21. Global Influenza NA Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Influenza NA Inhibitor Sales Volume Share by Application (2021-2032) Figure 23. Global Influenza NA Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Influenza NA Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Influenza NA Inhibitor Sales Value Share by Application (2021-2032) Figure 26. Global Influenza NA Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 27. Global Influenza NA Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Influenza NA Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Influenza NA Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Influenza NA Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 31. North America Influenza NA Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Influenza NA Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Influenza NA Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Influenza NA Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Influenza NA Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Influenza NA Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 37. South America Influenza NA Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Influenza NA Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Influenza NA Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Influenza NA Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Influenza NA Inhibitor Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Influenza NA Inhibitor Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Zanamivir
  • Peramivir
  • Oseltamivir
Applications
  • Influenza A Treatment
  • Influenza B Treatment
Companies covered
  • ATK Chemical
  • Chemwill Asia Co.,Ltd.
  • Green Cross
  • Moksha8 Pharma
  • NeoPharm
  • Shionogi Co.
  • GlaxoSmithKline
  • Henan DaKen Chemical
  • Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Influenza NA Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global Influenza NA Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global Influenza NA Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Influenza NA Inhibitor Market Dynamics
  1. 2.1 Influenza NA Inhibitor Industry Trends
  2. 2.2 Influenza NA Inhibitor Industry Drivers
  3. 2.3 Influenza NA Inhibitor Industry Opportunities and Challenges
  4. 2.4 Influenza NA Inhibitor Industry Restraints
3 Influenza NA Inhibitor Market by Company
  1. 3.1 Global Influenza NA Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global Influenza NA Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global Influenza NA Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global Influenza NA Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global Influenza NA Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global Influenza NA Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global Influenza NA Inhibitor Company Product Type and Application
  8. 3.8 Global Influenza NA Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Influenza NA Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Influenza NA Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Influenza NA Inhibitor Market by Type
  1. 4.1 Influenza NA Inhibitor Type Introduction
  2. 4.1.1 Zanamivir
  3. 4.1.2 Peramivir
  4. 4.1.3 Oseltamivir
  5. 4.2 Global Influenza NA Inhibitor Sales Volume by Type
  6. 4.2.1 Global Influenza NA Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Influenza NA Inhibitor Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Influenza NA Inhibitor Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Influenza NA Inhibitor Sales Value by Type
  10. 4.3.1 Global Influenza NA Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Influenza NA Inhibitor Sales Value by Type (2021-2032)
  12. 4.3.3 Global Influenza NA Inhibitor Sales Value Share by Type (2021-2032)
5 Influenza NA Inhibitor Market by Application
  1. 5.1 Influenza NA Inhibitor Application Introduction
  2. 5.1.1 Influenza A Treatment
  3. 5.1.2 Influenza B Treatment
  4. 5.2 Global Influenza NA Inhibitor Sales Volume by Application
  5. 5.2.1 Global Influenza NA Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Influenza NA Inhibitor Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Influenza NA Inhibitor Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Influenza NA Inhibitor Sales Value by Application
  9. 5.3.1 Global Influenza NA Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Influenza NA Inhibitor Sales Value by Application (2021-2032)
  11. 5.3.3 Global Influenza NA Inhibitor Sales Value Share by Application (2021-2032)
6 Influenza NA Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global Influenza NA Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Influenza NA Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Influenza NA Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global Influenza NA Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global Influenza NA Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Influenza NA Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global Influenza NA Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global Influenza NA Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global Influenza NA Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Influenza NA Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America Influenza NA Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Influenza NA Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe Influenza NA Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Influenza NA Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Influenza NA Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Influenza NA Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America Influenza NA Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Influenza NA Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Influenza NA Inhibitor Sales Value Share by Country, 2025 VS 2032
7 Influenza NA Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global Influenza NA Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Influenza NA Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Influenza NA Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global Influenza NA Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global Influenza NA Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global Influenza NA Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global Influenza NA Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global Influenza NA Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Influenza NA Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Influenza NA Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Influenza NA Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ATK Chemical
  2. 8.1.1 ATK Chemical Company Information
  3. 8.1.2 ATK Chemical Business Overview
  4. 8.1.3 ATK Chemical Influenza NA Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ATK Chemical Influenza NA Inhibitor Product Portfolio
  6. 8.1.5 ATK Chemical Recent Developments
  7. 8.2 Chemwill Asia Co.,Ltd.
  8. 8.2.1 Chemwill Asia Co.,Ltd. Company Information
  9. 8.2.2 Chemwill Asia Co.,Ltd. Business Overview
  10. 8.2.3 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product Portfolio
  12. 8.2.5 Chemwill Asia Co.,Ltd. Recent Developments
  13. 8.3 Green Cross
  14. 8.3.1 Green Cross Company Information
  15. 8.3.2 Green Cross Business Overview
  16. 8.3.3 Green Cross Influenza NA Inhibitor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Green Cross Influenza NA Inhibitor Product Portfolio
  18. 8.3.5 Green Cross Recent Developments
  19. 8.4 Moksha8 Pharma
  20. 8.4.1 Moksha8 Pharma Company Information
  21. 8.4.2 Moksha8 Pharma Business Overview
  22. 8.4.3 Moksha8 Pharma Influenza NA Inhibitor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Moksha8 Pharma Influenza NA Inhibitor Product Portfolio
  24. 8.4.5 Moksha8 Pharma Recent Developments
  25. 8.5 NeoPharm
  26. 8.5.1 NeoPharm Company Information
  27. 8.5.2 NeoPharm Business Overview
  28. 8.5.3 NeoPharm Influenza NA Inhibitor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 NeoPharm Influenza NA Inhibitor Product Portfolio
  30. 8.5.5 NeoPharm Recent Developments
  31. 8.6 Shionogi Co.
  32. 8.6.1 Shionogi Co. Company Information
  33. 8.6.2 Shionogi Co. Business Overview
  34. 8.6.3 Shionogi Co. Influenza NA Inhibitor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Shionogi Co. Influenza NA Inhibitor Product Portfolio
  36. 8.6.5 Shionogi Co. Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Influenza NA Inhibitor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Influenza NA Inhibitor Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Henan DaKen Chemical
  44. 8.8.1 Henan DaKen Chemical Company Information
  45. 8.8.2 Henan DaKen Chemical Business Overview
  46. 8.8.3 Henan DaKen Chemical Influenza NA Inhibitor Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Henan DaKen Chemical Influenza NA Inhibitor Product Portfolio
  48. 8.8.5 Henan DaKen Chemical Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Influenza NA Inhibitor Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Roche Influenza NA Inhibitor Product Portfolio
  54. 8.9.5 Roche Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Influenza NA Inhibitor Value Chain Analysis
  2. 9.1.1 Influenza NA Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Influenza NA Inhibitor Sales Mode & Process
  6. 9.2 Influenza NA Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Influenza NA Inhibitor Distributors
  9. 9.2.3 Influenza NA Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst